Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Wien Center for Clinical Research
mi
from
Miami Beach, FL
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Wien Center for Clinical Research
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
University of South Florida Health Byrd Alzheimer Institute
mi
from
Tampa, FL
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
University of South Florida Health Byrd Alzheimer Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
University of Kansas
mi
from
Fairway, KA
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
University of Kansas
mi
from
Fairway, KA
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
mi
from
Lexington, KY
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Boston University
mi
from
Boston, MA
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Boston University
mi
from
Boston, MA
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Lou Ruvo Center for Brain Health
mi
from
Las Vegas, NV
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Lou Ruvo Center for Brain Health
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
DENT Neurologic Institute
mi
from
Amherst, NY
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
DENT Neurologic Institute
mi
from
Amherst, NY
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve University
mi
from
Beachwood, OH
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve University
mi
from
Beachwood, OH
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Tulsa Clinical Research
mi
from
Tulsa, OK
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Tulsa Clinical Research
mi
from
Tulsa, OK
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Drexel University College of Medicine
mi
from
Philadelphia, PA
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Drexel University College of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Butler Hospital Memory & Aging Program
mi
from
Providence, RI
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Butler Hospital Memory & Aging Program
mi
from
Providence, RI
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Roper St. Francis Healthcare
mi
from
Charleston, SC
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Roper St. Francis Healthcare
mi
from
Charleston, SC
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
VA Palo Alto HSC / Stanford School of Medicine
mi
from
Palo Alto, CA
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
VA Palo Alto HSC / Stanford School of Medicine
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Bioclinica Research Orlando
mi
from
Orlando, FL
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Bioclinica Research Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Bioclinica Research North
mi
from
The Villages, FL
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Bioclinica Research North
mi
from
The Villages, FL
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Georgetown University
mi
from
Washington,
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated:  12/31/1969
Howard University
mi
from
Washington,
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial
Status: Enrolling
Updated: 12/31/1969
Howard University
mi
from
Washington,
Click here to add this to my saved trials
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Investigational Site Number 250001
mi
from
Garches,
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Investigational Site Number 250001
mi
from
Garches,
Click here to add this to my saved trials
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fairfax, VA
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Atlanta Egleston
mi
from
Atlanta, GA
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Atlanta Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Tucson, AZ
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Tampa, FL
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Atlanta, GA
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Boston, MA
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Athens,
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Athens,
Click here to add this to my saved trials
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Status: Enrolling
Updated:  12/31/1969
City of Hope
mi
from
Duarte, CA
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Status: Enrolling
Updated: 12/31/1969
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Institute (SCI)
mi
from
Stanford, CA
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Institute (SCI)
mi
from
Stanford, CA
Click here to add this to my saved trials